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Abstract
Background ENSURE-AF (NCT 02072434) assessed therapy with edoxaban versus enoxaparin–
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Objectives To evaluate clinical features and primary efficacy (composite of stroke, systemic 
embolic events, myocardial infarction and cardiovascular mortality during study period) and safety 
endpoints (composite of major and clinically relevant nonmajor bleeding during on-treatment 
period) in patients awaiting ECV of AF with a transesophageal echocardiography (TEE)-guided 
versus a non-TEE guided strategy. 
Methods In this prospective randomized open-label blinded endpoint study, 2199 patients were 
randomized to edoxaban 60 mg once daily (30 mg for creatinine clearance 15–50 mL/min, weight 
≤60 kg, and/or concomitant use of P-glycoprotein inhibitor) or enoxaparin–warfarin. Primary 
efficacy endpoint and safety endpoint were reported. Associates of TEE use, efficacy endpoint and 
safety endpoint were explored using multivariable logistic regression.
Results In total, 589 patients from the edoxaban stratum and 594 from the enoxaparin-warfarin 
stratum were allocated to the TEE-guided strategy. Primary efficacy was similar regardless of TEE 
approach (p = 0.575). There were no significant differences in bleeding rates, regardless of TEE 
approach (p = 0.677). Independent predictors of TEE use were: history of ischaemic stroke/ 
transient ischaemic attack, hypertension and valvular heart disease. Mean CHA2DS2VASc and 
HAS-BLED score were independent predictors of the efficacy endpoint whilst mean age was an 
independent predictor of the safety endpoint.
Conclusions Thromboembolic and bleeding events were not different between patients 
undergoing TEE-guided strategy and in those undergoing an optimized conventional 
anticoagulation approach for ECV of AF.
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Introduction
Oral anticoagulants (OAC) substantially decrease an inherent risk of stroke associated with 
electrical cardioversion (1, 2). According to the guidelines, patients without indications for long-
term anticoagulation who have atrial fibrillation (AF) longer than 48 hours should be treated with 
OAC at least 3 weeks before cardioversion and 4 weeks after it (3). In case of high CHA2DS2-
VASc score (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, 
stroke/transient ischaemic attack (TIA), vascular disease, age 65 to 74 years, sex category), this 
“window of opportunity” might be shorter. The presence of multiple stroke risk factors make the 
risk of thromboembolic complications unacceptably high (approximately 10%) when compared to 
patients without risk factors (1). The conversion of AF to sinus rhythm may result in 
thromboembolism even after short episodes (< 48 h) of the arrhythmia (4). Moreover, left atrial 
thrombi have been found on transesophageal echocardiography (TEE) in 4% of AF patients within 
the first 48 h of AF (5). 
In case of the necessity of early cardioversion, a TEE-guided strategy with abbreviated 
anticoagulation seems to be a viable alternative to conventional 3-week anticoagulation (6-8). TEE 
enables physicians to precisely diagnose or exclude thrombus in the left atrial appendage or in the 
other cardiac chambers. This strategy is particularly beneficial in very symptomatic AF patients 
because cardioversion can be performed quickly where there is a thrombus-negative TEE.  If 
thrombus in either the atrial appendage or the atrium is identified by the TEE, cardioversion 
should be delayed due to high risk of thromboembolism. OAC should be implemented for another 
4-12 weeks to allow thrombus resolution. Another TEE after prolonged anticoagulation should be 
considered in such cases to evaluate thrombus presence (8). Cardioversion may be safely 
performed in case of absence of thrombus (6). 
Current data support the use of rivaroxaban, dabigatran, apixaban or edoxaban or anticoagulation 
with optimally-managed vitamin K antagonists (VKA) [with International Normalised Ratio (INR) 
within range 2.0-3.0] in patients scheduled for cardioversion (7, 9, 10). The benefits of non-
vitamin K antagonist oral anticoagulants (NOACs) include a faster onset of action than VKA; 
also, there is no need for bridging during treatment, and no delay associated with waiting for a 
therapeutic INR because of no need of serial analysis of hemostatic parameters. However, strict 
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The EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation 
(ENSURE-AF) trial (NCT 02072434) was the largest prospective study of anticoagulation for 
patients with non-valvular AF scheduled for electrical cardioversion. The aim of this ancillary 
analysis from the ENSURE-AF trial was to evaluate the primary efficacy and safety endpoints in 
patients awaiting elective electrical cardioversion of AF with a TEE-guided versus a non-TEE 
guided strategy.
Methods
The design of the ENSURE-AF trial (NCT 02072434) have been described previously (11, 12). It 
was a multicenter, prospective, randomized, open-label, blinded endpoint evaluation trial where 
patients with non-valvular AF (of duration from 48 hours to 12 months) undergoing elective 
electrical cardioversion were randomized (1:1) to receive either edoxaban 60 mg once-daily (QD; 
30 mg QD for creatinine clearance [CrCl] of 15–50 mL/min, weight ≤60 kg, and/or concomitant 
use of P-glycoprotein inhibitor) or enoxaparin-warfarin within each stratum (ie, stratification 
according to cardioversion approach to TEE-guided or non–TEE-guided group). The intention of 
the enrolment was to achieve the balance of therapy assignment within each group. Patients were 
stratified to TEE-guided group or non-TEE-guided group, as determined by the local investigator 
and local standard clinical practice (at the discretion of individual investigators at local centres). 
There was no mandated standardised protocol.
Study investigators, statisticians and patients were not masked to the treatment allocation while the 
adjudication committee was. 
In the TEE-guided group, TEE and cardioversion had to be done within 3 days of randomization, 
but could be performed on the same day. Enoxaparin and warfarin (minimum of 1 dose each) had 
to be continued before cardioversion in patients in the enoxaparin-warfarin group until INR of 2.0 
or greater was achieved. The treatment with warfarin was adjusted to maintain the therapeutic INR 
level of 2.0-3.0 with INR measurements once every 2-3 days until reaching the therapeutic range. 
A special algorithm for the management of patients with labile INR was designed and 
implemented. In the enoxaparin-warfarin group, warfarin was continued from the time of 
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In patients allocated to the edoxaban group, the anticoagulation had to be started at least 2 hours 
before cardioversion. The next dose of edoxaban was planned for the day after cardioversion and 
then every 24 hours up to day 28 after electrical cardioversion. 
In all subjects, cardioversion was planned at a minimum of 21 days from the start of treatment. In 
the edoxaban group, patients were treated with edoxaban for a minimum of 21 days before 
cardioversion followed by the procedure and an additional 28 days of treatment. In case of 
spontaneous cardioversion (defined as confirmation of sinus rhythm in 12 lead electrocardiogram) 
in the preprocedural time patients have to complete 28 days of management from the day of 
spontaneous cardioversion appeared and 30 days of follow-up.
In case of thrombi on TEE, patients had the opportunity to complete 28 days of study medication. 
All patients were followed-up for safety for 30 days after finishing or discontinuing the therapy.
All patients with a CHA2DS2-VASc score ≥2 and male subjects with CHA2DS2-VASc score =1 
(where the use of OAC is preferred over aspirin) will require to be transitioned at the end of the 
study treatment to a standard-of-care anticoagulant consistent with current guidelines on stroke 
prevention in patients with AF (8, 13). These subjects will receive the treatment chosen by the 
investigator.
The primary efficacy endpoint was defined as a composite of stroke, systemic embolic event 
(SEE), myocardial infarction (MI), and cardiovascular death analysed during the overall study 
period, 28 days on study drug after cardioversion and then follow-up was performed for safety for 
another 30 days after finishing or discontinuing the medication. The primary safety endpoint was 
defined as the composite of major and clinically relevant nonmajor bleeding (CRNM) analysed 
during the on-treatment period from the time of first dose to last dose of study drug taken + 3 
days. The primary safety endpoint was evaluated in patients who received ≥ 1 dose of the study 
drug. 
The study protocol was compliant with the Declaration of Helsinki and the International 
Conference on Harmonization consolidated guideline E6 for Good Clinical Practice 
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Statistical analysis
The primary efficacy analysis was performed on the intention-to-treat population . Efficacy 
outcomes were analyzed during the overall study period . All patients who took at least one dose 
of study drug  were included in primary safety analysis. Safety outcomes were analyzed during the 
on-treatment period, defined as the time period the subject was taking study medication plus up to 
3 days after their last dose for that time period. Demographic and clinical characteristics were 
summarized by TEE- and non–TEE-guided ECV. Sensitivity analyses were calculated in the per-
protocol population of all randomly assigned patients without any predefined major protocol 
deviations. The association of baseline characteristics variables with the TEE use was evaluated 
using univariate logistic regression analyses. The variables with statistically significant association 
on univariate logistic regression analysis were entered into multivariable logistic regression 
models to identify multivariable predictors of TEE use. The selected variables were included as 
predictors of efficacy endpoint or safety endpoint in a stepwise logistic regression analysis. A 
significance level of 0.1 is required to allow a variable into the model and for a variable to stay in 
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Results
In this study, 2,199 patients were enrolled from 2014 to 2015, from 239 centers in 19 countries in 
Europe and the United States of America: 1,095 patients were randomized to edoxaban and 1,067 
of them received study drug whilst 1,104 patients were randomized to enoxaparin-warfarin group 
and 1,082 subjects received study drug.  From the TEE-guided stratum, 589 patients were 
randomized to edoxaban and 594 to enoxaparin-warfarin.
Patients in the TEE-guided group were more likely to be older (p=0.0358) and to have a higher 
mean CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, 
stroke/transient ischaemic attack (TIA), vascular disease, age 65 to 74 years, sex category) score 
(p=0.0046), CHA2DS2-VASc score ≥ 5 (p=0.0165), hypertension (p=0.0181), ischaemic stroke / 
transient ischaemic attack (TIA) (p=0.0077) and valvular heart disease (defined as aortic stenosis, 
aortic regurgitation, mitral regurgitation or mitral valve prolapse) (p < 0.0001) than those in non-
TEE guided group, Table 1. There were no significant differences in mean HAS-BLED 
(hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile 
International Normalised Ratio, elderly (age > 65 years), drugs or alcohol concomitantly) score 
(Table 1).
There were 89 (47 in edoxaban and 42 in warfarin) patients who had a thrombus seen during the 
TEE. No patients with thrombus had stroke, SEE, MI or CV mortality (the composite of Stroke, 
SEE, MI and CV Mortality is the primary efficacy endpoint).
Patients in Austria, Belgium, Bulgaria, Czech Republic, Germany, France, Hungary, Poland and 
Russia were more likely to be stratified to TEE-guided group whilst patients in Denmark, Spain, 
United Kingdom, Israel, Italy, Netherlands and Sweden were more likely to be stratified to non-
TEE approach (Table 2).  None of the patients included from the UK were entered into the TEE-
guided stratum.
Stroke, systemic embolic events (SEE), myocardial infarction (MI) or cardiovascular mortality 
occurred in 7 (0.59%) patients in the TEE-guided group and in 9 (0.89%) patients in the non-TEE-
guided group [odd ratio (OR) 0.67, 95% confidence interval (CI) 0.21-2.02, p=0.575) (Table 3). 
Major or clinically relevant non-major bleeding (CRNM) appeared in 16 (1.39%) patients in the 
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0.55-3.05, p=0.677) (Table 3). Major bleeding events occurred in 5 (0.44%) patients in the TEE-
guided group and in 3 (0.30%) patients in the non-TEE-guided group (OR 1.46, 95% CI 0.28-9.41, 
p=0.878) (Table 3).
Factors associated with TEE use were history of ischaemic stroke / TIA, hypertension and valvular 
heart disease (Table 4).  Associates of the efficacy endpoint were mean HAS-BLED and 
CHA2DS2VASc scores, whereas the main associate of the safety endpoint was age (see Table 5).
Discussion
In this large, prospectively collected dataset of anticoagulation for patients with nonvalvular AF 
scheduled for electrical cardioversion, overall rates of major cardiovascular and bleeding events 
were low. Second, there were no significant differences in safety and efficacy outcomes between 
TEE-guided and non-TEE-guided group scheduled for electrical cardioversion of nonvalvular AF. 
This large multinational trial also provides insights into country practice differences with regard to 
the popularity of TEE-guided cardioversion, and the clinical predictors of TEE use for 
cardioversion.
Patients stratification according to cardioversion approach (TEE or non-TEE) reflected country-
specific routine standards of care and preferences. As an example, all patients in the UK were 
stratified to non-TEE approach whilst all patients in Belgium and approximately all patients in 
Germany and Hungary were stratified to TEE approach. A similar percentage of patients were 
qualified to TEE and non-TEE strategy in Ukraine and the United States of America.
In the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) 
Multicenter Study (6), a conventional stroke prevention strategy with warfarin for 3 weeks was 
compared to TEE-guided strategy with short-term  anticoagulation (unfractioned heparin 
intravenous or warfarin). There were no significant differences between the two strata in the rate 
of embolic events. There was no significant difference between groups in terms of death from 
cardiac causes. TEE-guided group had fewer total haemorrhagic events than the non-TEE guided 
group. Unfortunately, the ACUTE study was stopped early and was underpowered to report 
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Data on the primary outcome (defined as ischaemic stroke and systemic embolism) in patients 
with TEE-guided cardioversion and with cardioversion without TEE were provided in the post-hoc 
analysis of data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in 
Atrial Fibrillation (ARISTOTLE) (14). There was no ischaemic stroke and systemic embolism in 
both groups. Of note,  the prevalence of congestive heart failure was lower than in the ENSURE-
AF.
In the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study the number 
of patients medicated in each arm according to TEE approach was not available and some patients 
had more than one cardioversion (15, 16). In one systematic review and meta-analysis (17), the 
subgroup analysis of the primary outcomes (defined as ischaemic stroke and systemic embolism) 
according to the use of TEE was performed. Results from ARISTOTLE (14), RE-LY (15) and 
EXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of 
caRdiovascular events in patients with non-valvular aTrial fibrillation scheduled for cardioversion 
(X-VERT) (7) trials were analysed. RE-LY reported 2 primary outcomes in the TEE-guided group 
(1 of which in VKA arm and 1 in NOAC arm, risk ratio (RR) 0.27, 95% confidence interval (CI) 
0.02-4.21) and 9 primary outcomes in non-TEE-guided group (6 of which in NOAC arm and 3 in 
VKAs arm, RR 1.16, 95% CI 0.29-4.63), whilst X-VERT reported 2 primary outcomes in TEE-
guided group (0 in NOAC arm and 2 in VKA arm, RR 0.11, 95% CI 0.01-2.21) and 1 event in 
non-TEE-guided group (in the VKA arm, RR 0.16, 95% CI 0.01-3.94). In this meta-analysis, 
patients medicated with NOACs with TEE-guided cardioversion had a non-significant RR 0.18 
[95% CI 0.02-1.35). This estimate did not differ from pooled analysis of NOACs versus VKA in 
subjects with non-TEE guided cardioversion (RR 0.75, 95% CI 0.15-3.76). 
In our analysis, electrical cardioversion preceded by TEE-guided approach was comparably safe to 
non-TEE guided strategy with strict adherence to OAC therapy. In the above mentioned meta-
analysis there was a trend towards higher safety of TEE-guided strategy which could be related to 
underpowered comparisons. 
Similarly to our study, in the Flecainide Short-Long Trial (18) the type of treatment prior to 
planned elective cardioversion of persistent AF (TEE-guided approach versus anticoagulation 
before and after the procedure) did not affected stroke rate. Unfortunately, bleeding events before 
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Thromboembolic and bleeding events were similar in both groups in our study probably because 
of optimal use of enoxaparin-warfarin therapy with acceptable time in therapeutic range and high 
compliance (of more than 99%) associated with management with edoxaban. The very good 
quality of anticoagulation therapy is one of the strengths of our study. Another strength of the trial 
is its prospective design which is the largest dataset comparing a NOAC (edoxaban) to warfarin in 
terms of efficacy and safety in the peri-cardioversion period.
Our study shows that factors associated with TEE use were history of ischaemic stroke / TIA, 
hypertension and valvular heart disease. TEE enables the visualization of thrombus in cardiac 
chambers. All forms of valvular heart diseases accompanying AF, except of mitral stenosis,  do 
not seem to elevate the risk of thrombo-embolism beyond the level entailed by AF alone, and do 
not seem to be additional risk factors (19). Ischaemic stroke / TIA and hypertension are 
thromboembolic factors. Left atrial thrombus is present in approximately 10% of patients with 
nonvalvular AF and its presence is associated with a higher mean age, and greater prevalence of 
female gender, hypertension, diabetes mellitus and chronic heart failure (20).
For the efficacy endpoint, mean HAS-BLED and mean CHA2DS2VASc score were associates of 
outcome. Thus, the need for strict adherence to the OAC therapy has to be emphasized to patients, 
particularly to those with high HAS-BLED and mean CHA2DS2VASc score. Those patients 
should have been regularly reminded by physicians about the significance of OACs in stroke 
prevention.   Regular re-assessment should be a part of a comprehensive and holistic approach to 
the management of high risk patients with AF which is The Atrial fibrillation Better Care (21).
In our study age was the predictor of safety endpoint. Patients aged ≥ 75 years have elevated risk 
for stroke and major bleeding, but the Birmingham Atrial Fibrillation Treatment of the Aged 
Study (BAFTA) (22), a randomized controlled trial of warfarin versus aspirin for stroke 
prevention in octogenarians with AF (WASPO) (23) and some other randomized controlled trials 
support the use of VKAs or NOACs in AF patients aged ≥ 75 years (24).
Limitations
This study has some limitations that should be described. The main limitation of the study is the 
non-randomized allocation to either of the two strategies (TEE-guided approach, non-TEE guided 
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is informative, but far from conclusive.  Country-specific stratification may express routine 
standards of care. There was no mandated standardised protocol.
Possibly, patients with greater probability of thrombus in left atrium may have been stratified to 
TEE-approach. Furthermore, the ENSURE-AF study was underpowered to show statistically 
significant differences for efficacy or safety endpoints. Moreover, the open-label study design 
might be related with bias in reporting outcome. Limited follow-up period appears to be also one 
of the study limitations.
Conclusions
There are country practice differences with regard to the popularity of TEE-guided cardioversion, 
and the clinical predictors of using this strategy. Major cardiovascular events and bleeding 
outcomes were similar in patients undergoing TEE-guided strategy relative to those undergoing an 
optimized conventional anticoagulation approach for electrical cardioversion of AF, despite a 
higher CHA2DS2-VASc score and more prevalent valvular heart disease and prior stroke in the 
former.
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Table 1. Baseline demographics according to electrical cardioversion approach 
Variable TEE-guided group 
n = 1183 
Non-TEE-guided 
group 
n = 1016 
p-value 
Age, mean ± SD 64.7±10.8 63.7±10.2 0.0358 
Age ≥ 75 years, n 
(%) 
222 (18.8) 137 (13.5) 0.0008 
Male sex, n (%) 774 (65.4) 669 (65.8) 0.8364 
CHA2DS2-VASc, 
mean ± SD 
2.7±1.5 2.5±1.4 0.0046 
CHA2DS2-VASc ≥ 
5, n (%) 
42 (3.6) 19 (1.9) 0.0165 
Ischaemic 
stroke/TIA, n (%) 
87 (7.4) 47 (4.6) 0.0077 
Hypertension, n 
(%) 
945 (79.9) 769 (75.7) 0.0181 
Diabetes, n (%) 220 (18.6) 195 (19.2) 0.7217 
Congestive heart 
failure, n (%) 
517 (43.7) 443 (43.6) 0.9624 
Myocardial 
infarction, n (%) 
73 (6.2) 74 (7.3) 0.2976 
Valvular heart 
disease 
339 (28.7) 151 (14.9) <0.0001 
HAS-BLED, mean 
± SD 
0.9±0.80 0.9±0.77 0.2471 
TEE, transesophageal echocardiography, CHA2DS2-VASc; congestive heart failure, 
hypertension, age ≥ 75 years, diabetes, stroke/transient ischemic attack (TIA), vascular 
disease, age 65 to 74 years, sex category, HAS-BLED: hypertension, abnormal renal/liver 
function, stroke, bleeding history or predisposition, labile International Normalised Ratio, 
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Table 2. Country-specific stratification of patients according to electrical cardioversion 
approach 
Country, n (%) Non-TEE TEE Total 
Austria 6 (18.8) 26 (81.3) 32 
Belgium 0 (0.0) 41 (100.0) 41 
Bulgaria 42 (33.6) 83 (66.4) 125 
Czech Republic 80 (46.2) 93 (53.8) 173 
Germany 4 (3.3) 119 (96.8) 123 
Denmark 43 (75.4) 14 (24.6) 57 
Spain 92 (64.8) 50 (35.2) 142 
France 10 (25.6) 29 (74.4) 39 
United Kingdom 159 (100.0) 0 (0.0) 159 
Hungary 1 (0.6) 178 (99.4) 179 
Israel 51 (62.2) 31 (37.8) 82 
Italy 47 (68.1) 22 (31.9) 69 
Netherlands 42 (89.4) 5 (10.6) 47 
Poland 12 (22.2) 42 (77.8) 54 
Russia 48 (39.3) 74 (60.7) 122 
Sweden 9 (64.3) 5 (35.7) 14 
Ukraine 220 (51.2) 210 (48.8) 430 
United States of 
America 
49 (51.6) 46 (48.4) 95 
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Table 3. Efficacy and safety outcomes rates according to electrical cardioversion approach 
 TEE-guided group 
n = 1183 
Non-TEE-guided 
group 
n = 1016 
p-value 




   
N 1183 1016  
n (%) 7 (0.59) 9 (0.89)  
OR (95% CI)  0.67 (0.21-2.02) 0.575 
Major or CRNM 
bleeding events 
   
N 1147 1002  
n (%) 16 (1.39) 11 (1.10)  
OR (95% CI) 1.27 (0.55-3.05) 0.677 
Major bleeding 
events 
   
N 1147 1002  
n (%) 5 (0.44) 3 (0.30)  
OR (95% CI) 1.46 (0.28-9.41) 0.878 
 
CRNM, clinically relevant non-major bleeding, MI, myocardial infarction, OR, odds ratio, 
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Table 4. Independent predictors of the use of TEE 
 Multivariate analysis 




attack (no versus 
yes) 
0.66 0.45-0.95 0.027 
Hypertension (no 
versus yes) 
0.80 0.65-0.98 0.031 
Valvular heart 
disease (no versus 
yes) 
0.44 0.35-0.54 <0.001 
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Table 5. Independent predictors of safety or efficacy endpoints 
 Multivariate analysis 
 OR 95% CI p-value 
Predictors of safety endpoints 
Age 1.05 1.01-1.09 0.022 




1.47 1.01-2.12 0.042 
Mean HAS-BLED 
score 
1.78 0.95-3.33 0.073 
CHA2DS2-VASc, congestive heart failure, hypertension, age ≥ 75 years, diabetes, 
stroke/transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category CI, 
confidence interval, HAS-BLED, hypertension, abnormal renal/liver function, stroke, 
bleeding history or predisposition, labile International Normalised Ratio, elderly (age > 65 
years), drugs or alcohol concomitantly OR, odds ratio 
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